Phosphodiesterase enzyme inhibitors (PDEIs) are most commonly prescribed by urologists for the treatment of erectile dysfunction. They are also gaining popularity as a treatment for lower urinary tract symptoms, based on their effect on smooth muscles – either vascular smooth muscles or smooth muscles in the urinary tract. For vascular smooth muscles, they cause vasodilation, enhanced microcirculatory haemodynamics through inhibition of platelet aggregation and adhesion, induction of apoptosis of adhesion fibroblasts and a reduction in the scarring process.
Methodology:
We reviewed articles published in English and indexed in the PubMed, Embase and Google Scholar databases, and consulted textbooks. Key search terms used were: urethral stricture, anti-fibrotic, scar-modulating agent, PDEIs, urethral scarring and urethroplasty. We created a synopsis of relevant articles, including original research studies and reviews.
ChengLLiSWangZ, et al. A brief review on anterior urethral strictures. Asian J Urol2018; 5: 88–93.
7.
TaljaMVirtanenJAnderssonLC.Toxic catheters and diminished urethral blood circulation in the induction of urethral strictures. Eur Urol1986; 12: 340–345.
8.
LumenNHoebekePWillemsenP, et al. Etiology of urethral stricture disease in the 21st century. J Urol2009; 182: 983–987.
9.
SimsekAAldamanhoriRChappleCR, et al. Overcoming scarring in the urethra: Challenges for tissue engineering. Asian J Urol2018; 5: 69–77. https://doi.org/10.1016/j.ajur.2018.02.002
10.
AngerJTBuckleyJCSantucciRA, et al. Trends in stricture management among male Medicare beneficiaries: underuse of urethroplasty?Urology2011; 77: 481–485.
11.
SinghMBlandyJP.The pathology of urethral stricture. J Urol1976; 115: 673–676.
12.
BaskinLSConstantinescuSCHowardPS, et al. Biochemical characterization and quantitation of the collagenous components of urethral stricture tissue. J Urol1993; 150: 642–647.
13.
CavalcantiAGYucelSDengDY, et al. The distribution of neuronal and inducible nitric oxide synthase in urethral stricture formation. J Urol2004; 171: 1943–1947.
14.
Da-SilvaEASampaioFJBDornasMC, et al. Extracellular matrix changes in urethral stricture disease. J Urol2002; 168: 805–807.
15.
MingqiangZXuyuXRuizhiX, et al. Inhibition of a calcium channel blockers on human urethral scars in vitro andin vivo. Int J Clin Exp Med2018; 11: 7897–7906.
16.
TavakkoliTKYarmohamadiAMohammadiS.Triamcinolone injection following internal urethrotomy for treatment of urethral stricture. Urol J2011; 8: 132–136.
17.
FarrellMRLawrenzCWLevineLA.Internal urethrotomy with intralesional mitomycin C: an effective option for endoscopic management of recurrent bulbar and bulbomembranous urethral strictures. Urology2017; 110: 223–227.
18.
KraneLSGorbachinskyISirintrapunJ, et al. Halofuginone-coated urethral catheters prevent periurethral spongiofibrosis in a rat model of urethral injury. J Endourol2011; 25: 107–112.
19.
GrudzienMMLowPSManningPC, et al. The antifibrotic drug halofuginone inhibits proliferation and collagen production by human leiomyoma and myometrial smooth muscle cells. Fertil Steril2010; 93: 1290–1298.
20.
ValenteEGVernetDFerriniMG, et al. l-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide2003; 9: 229–244.
21.
KutukMSOzgunMTBatukanC, et al. Oral tadalafil reduces intra-abdominal adhesion reformation in rats. Hum Reprod2012; 27: 733–737.
22.
SchepersMTianeAPaesD, et al. Targeting phosphodiesterases – towards a tailor-made approach in multiple sclerosis treatment. Front Immunol2019; 10: 1727.
23.
TapiaESanchez-LozadaLGSotoV, et al. Sildenafil treatment prevents glomerular hypertension and hyperfiltration in rats with renal ablation. Kidney Blood Press Res2012; 35: 273–280.
24.
GiulianoFÜckertSMaggiM, et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol2013; 63: 506–516.
25.
GacciMSebastianelliASalviM, et al. PDE5-Is for the treatment of concomitant ED and LUTS/BPH. Curr Bladder Dysfunct Rep2013; 8: 150–159.
26.
KediaGTÜckertSJonasU, et al. The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol2008; 26: 603–609.
27.
LinC-SAlbersenMXinZ, et al. Phosphodiesterase-5 expression and function in the lower urinary tract: a critical review. Urology2013; 81: 480–487.
28.
FibbiBMorelliAVignozziL, et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med2010; 7: 59–69.
29.
ÜckertSWaldkirchESKuczykMA, et al. 549 Phosphodiesterase type 5 is co-localized with key proteins of the nitric oxide/cyclic gmp signaling in the human prostate. Eur Urol Suppl2011; 10: 182.
30.
SchwarzE.The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. Vasc Health Risk Manag2010; 6: 273–280.
31.
RavipatiGMcClungJAAronowWS, et al. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Cardiol Rev2007; 15: 76–86.
32.
SandnerPStaschJP.Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence. Respir Med2017; 122: S1–S9.
33.
CakirTOzerIBostanciEB, et al. Increased collagen maturity with sildenafil citrate: experimental high risk colonic anastomosis model. Int J Surg2015; 13: 152–156.
34.
KurtOYesildagEYaziciCM, et al. Effect of tadalafil on prevention of urethral stricture after urethral injury: an experimental study. Urology2016; 91: 243.e1–243.e6.
35.
SangkumPLevyJYafiFA, et al. Erectile dysfunction in urethral stricture and pelvic fracture urethral injury patients: diagnosis, treatment, and outcomes. Andrology2015; 3: 443–449.
36.
AnderssonK-E. PDE5 inhibitors – pharmacology and clinical applications 20 years after sildenafil discovery. Br J Pharmacol2018; 175: 2554–2565.
